TREATMENT OF RELAPSED/REFRACTORY AGGRESSIVE NON‐HODGKIN LYMPHOMA (NHL) WITH LISOCABTAGENE MARALEUCEL IN THE OUTPATIENT SETTING: RESULTS FROM TWO PHASE 2 TRIALS von Sehgal, A., Godwin, J.E., Maris, M.B., Hildebrandt, G.C., Trede, N.S., Kostic, A., Wang, L., Lymp, J., Bachier, C.R.

Volltext

PS1533 KD025–208: A PHASE 2A TRIAL OF KD025 FOR PATIENTS WITH CHRONIC GRAFT‐VERSUS‐HOST DISEASE (CGVHD) – UPDATED SAFETY AND EFFICACY von Salhotra, A., Zoghi, B., Essell, J., Bachier, C.R., Weisdorf, D.J., Lazaryan, A., Green, L.S., Schueller, O., Huang, L., Yang, Z., Eiznhamer, D., Aggarwal, S.K., Blazar, B.R., Lee, S.J., Jagasia, M.

Volltext

359: Immune Activation with Interleukin-2 and Granulocyte-Macrophage Colony Stimulating Factor for Treatment of Relapse after Allogeneic Stem Cell Transplantation von Bachier, C.R, Shaughnessy, P, Smith, B, Salinas, R, LeMaistre, C.F

Volltext

Interleukin-2 (IL-2) and granulocyte-macrophage stimulating factor (GM-CSF) for treatment of relapse after allogeneic stem cell transplant (ASCT) von Bachier, C.R., Shaughnessy, P., Wall, D., Grimley, M., LeMaistre, C.F.

Volltext